Oxford Biomedica PLC Total Voting Rights (5453Z)
03 September 2018 - 6:18PM
UK Regulatory
TIDMOXB
RNS Number : 5453Z
Oxford Biomedica PLC
03 September 2018
Oxford BioMedica
Total Voting Rights
Oxford, UK - 3 September 2018: Oxford BioMedica plc ("Oxford
BioMedica" or "the Company") (LSE: OXB), announces that in
accordance with the FCA's Disclosure and Transparency Rule 5.6.1,
the Company's issued share capital as at the close of business on
31 August 2018 consisted of 66,039,775 ordinary shares of 50 pence
each ("Ordinary Shares"). There are no Ordinary Shares held in
treasury.
Accordingly, the total number of voting rights in Oxford
BioMedica plc at the date of this notice is 66,039,775.
The above figure (66,039,775) may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, Oxford BioMedica plc under the FCA's Disclosure and
Transparency Rules.
- Ends -
For further information, please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Stuart Paynter, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/ 3709 5700
Olivia Manser/Laura Thornton
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Bioverativ, Sanofi, Axovant,
Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene
Therapy Consortium/Imperial Innovations, GC LabCell and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
320 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVREAPNDEFPPEEF
(END) Dow Jones Newswires
September 03, 2018 04:18 ET (08:18 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024